[Lp(a)] to cell surface receptors was studied on cultured human fibroblasts. The results were compared with corresponding data obtained with 1251-low density lipoproteins (LDL). Equilibrium binding studies showed that Lp(a) is bound with high affinity by the cell surface receptors. The maximum binding capacity for Lp(a) was 37% lower than for LDL. For Lp(a) and LDL, the Scatchard plots displayed linearity, indicating a single category of binding sites. Half-maximal saturation occurred at a concentration of 9.52±1.04 nM for Lp(a) and 7.76±1.29 nM for LDL. Competition binding experiments revealed that Lp(a) and LDL are nearly equally potent in competing each other for the binding sites. Binding of Lp(a) and LDL were followed by suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Cyclohexanedione treatment of Lp(a) and LDL completely abolished receptor binding. Neither Lp(a) nor LDL were specifically bound by fibroblasts obtained from a patient with homozygous familial hypercholesterolemia (FH).
A B S T R A C T The binding of '25I-lipoprotein (a)
[Lp(a)] to cell surface receptors was studied on cultured human fibroblasts. The results were compared with corresponding data obtained with 1251-low density lipoproteins (LDL). Equilibrium binding studies showed that Lp(a) is bound with high affinity by the cell surface receptors. The maximum binding capacity for Lp(a) was 37% lower than for LDL. For Lp(a) and LDL, the Scatchard plots displayed linearity, indicating a single category of binding sites. Half-maximal saturation occurred at a concentration of 9.52±1.04 nM for Lp(a) and 7.76±1.29 nM for LDL. Competition binding experiments revealed that Lp(a) and LDL are nearly equally potent in competing each other for the binding sites. Binding of Lp(a) and LDL were followed by suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase activity. Cyclohexanedione treatment of Lp(a) and LDL completely abolished receptor binding. Neither Lp(a) nor LDL were specifically bound by fibroblasts obtained from a patient with homozygous familial hypercholesterolemia (FH).
The removal mechanisms for Lp(a) and LDL were further compared by in vivo studies. Radioiodinated Lp(a) and LDL were injected intravenously into 12 normolipemic individuals to measure kinetic parameters of these two lipoproteins simultaneously in each subject. Mean fractional catabolic rate (FCR) of Lp(a) was 0.260±0.060 and mean FCR of LDL was 0.377±0.077 (mean±SD). In each subject, FCR of Lp(a) was lower than the FCR of LDL; the mean difference was 31%. The absolute synthetic rate of Lp(a) was significantly lower than the corresponding value of LDL. In each individual, the percentage of total Lp(a) that was contained in the intravascular space was higher than the corresponding value of LDL; the mean difference was 19%. A highly significant positive Received for publication 5 October 1981 and in revised form 13 December 1982. correlation was found between FCR of LDL and FCR of Lp(a) (r = 0.853, P < 0.01). No relationship was found between the serum concentration of LDL-apolipoprotein B and Lp(a). The serum level of Lp(a) was positively related to the absolute rate of Lp(a) synthesis (r = 0.979, P < 0.01). The serum level of LDL-apolipoprotein B was inversely related to FCR of LDL (r = 0.613, P < 0.05). In a patient with homozygous FH, FCR of LDL was 0.205 and FCR of Lp(a) was 0.210.
The results of these studies show that Lp(a) is specifically bound with high affinity to the same receptors of human fibroblasts as LDL. The affinity and maximum binding capacity are slightly lower for Lp(a) than for LDL. The results of the turnover studies are consistent with the assumption that Lp(a) is removed from the plasma by similar mechanisms as LDL.
INTRODUCTION
Lipoprotein (a) [Lp(a)]' is a lipoprotein which originally was believed to represent a genetic variant of low density lipoprotein (LDL) or better, lipoprotein B (Lp B) (1) . In later studies, Lp(a) was found to be a separate lipoprotein that can be demonstrated with sensitive immunological methods in the serum of all individuals containing apolipoprotein B (2) . Lp(a) has gained great clinical interest since many studies have shown a relationship between the serum level of Lp(a) and coronary vascular disease (1, (3) (4) (5) .
Lp(a) has many physicochemical properties in common with LDL (d = 1.006-1.063 g/ml). Most of the plasma Lp(a) is found in the density range of 1.055 to 1.100 g/ml. The lipid composition of Lp(a) and LDL are nearly identical (6) (7) (8) . The hexose, hexosamin, and sialic acid content, however, are significantly higher in Lp(a) (9) . The main protein constituent of both lipoproteins is apolipoprotein B. Lp(a) has an additional apoprotein that has been termed "specific Lp(a) antigen" (9-11). On agarose gel or cellulose acetate Lp(a) migrates somewhat faster than LDL and has therefore also been described as -pre-fl-lipoprotein" (3, 4, 12) .
In spite of these remarkable similarities between Lp(a) and LDL, Lp(a) is not a metabolic product of very low density lipoproteins (VLDL), LDL, or chylomicrons, but seems to be synthesized as a separate lipoprotein (13) . Furthermore, serum Lp(a) is not converted to other serum lipoproteins (14) . Recently, some kinetic parameters of Lp(a) have been reported (14) . Again some similarities between Lp(a) and LDL exist: the mean fractional catabolic rate (FCR) of Lp(a) and the average percentage of the total Lp(a) pool that is in the circulation (percent intravascular) were equal or only slightly different from the corresponding values of LDL reported by others (15) (16) (17) (18) .
Goldstein and Brown (19) discovered specific receptors with high affinity for LDL on the cell surface of human fibroblasts. These receptors, which also exist on other cell types including smooth muscle cells (20) , lymphocytes (21) , and endothelial cells (22) , play a major role in the removal and catabolism of LDL (23) . Binding of LDL to the specific surface receptors is the first and rate limiting step in the LDL pathway, followed by endocytosis of the lipoprotein, utilization of its cholesterol and suppression of endogenous cholesterol synthesis within the cell (24) . It is well established that the recognition site for binding of the LDL particle to the receptor resides with apoprotein B (25) .
To date, the mechanism of Lp(a) catabolism has not been clarified. Since (27) found that a lipoprotein fraction with an electrophoretic mobility on agarose between fl-and pre-B-lipoproteins is bound, internalized, and degraded by cultured human fibroblasts. In this study, however, the isolated lipoprotein fraction was not identified as Lp(a) by immunological methods and no quantitative binding data were presented. Floren et al. (28) found that Lp(a) is able to stimulate cholesterol esterification and to increase cholesterol content in cultured human fibroblasts. The authors speculate that Lp(a) enters fibroblasts via the LDL receptor pathway since no effect on cholesterol content was observed when the study was 
METHODS

Binding studies
Isolation of Lp(a) and LDL. The details of the method for isolation of Lp(a) and LDL were described recently (14) . Plasma was obtained by plasmapheresis from healthy volunteers who had high levels of Lp(a) as checked by doubleimmunodiffusion using monospecific anti-Lp(a) antibodies (14) . The plasma was subjected to sequential ultracentrifugation to obtain density fractions from 1.006 to 1.055 g/ml and from 1.055 to 1.110 g/ml. The densities were adjusted by addition of solid NaCl and checked with a density meter (Anton Paar K. G., Graz). All centrifugal procedures were performed in a Beckman L8-70 centrifuge using a Ti 50.2 rotor (Beckman Instruments, Inc., Fullerton, CA). The supernatants, containing the lipoproteins of the d 1.006-1.055 g/ml and 1.055-1.110 g/ml, were collected by tube slicing. These fractions were concentrated to a volume of -5 ml by dialysis against polyethyleneglycol and then applied to an agarose column (Bio Gel A-Sm, Bio-Rad Laboratories, Richmond, CA). Elution of the lipoproteins was performed with 0.15 M NaCl, pH adjusted to 8.5 by addition of NH40H. During all steps of the isolation procedure, Na2EDTA and NaN3 were present in a concentration of 1 mg/ml. The elution profile and the characterization of the eluted Lp(a) peak have been described previously (14) .
Jodination of Lp(a) and LDL. Fractions containing the isolated Lp(a) or LDL were dialyzed against 0.1 M glycine buffer, pH 10, and then iodinated with 1251 according to the McFarlane method (29) as modified by Bilheimer et al. (30) . Free iodine was removed by filtration on Sephadex G-25 and subsequent dialysis against 0.15 M NaCl with several bath changes. The whole procedure of the isolation and iodination took 4 d. Labeled Lp(a) and LDL were characterized by the same methods as described recently (14) . Most of the radioactivity was bound to the apoprotein; only 0.5-3% was found in the lipid moiety after extraction with chloroform-methanol (2:1).
3-Hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase assay. HMG-CoA reductase activity was determined as described by Brown et al. (31) with some modifications (32) .
Chemical modification of Lp(a) and LDL with 1,2-cyclohexanedione (25). 5 mg of Lp(a) or LDL in 1 ml 0.15 M NaCl containing 0.01% Na2EDTA were mixed with 2 ml 0.15 M 1,2-cyclohexanedione in 0.2 M sodium borate buffer, pH 8.1, and incubated at 37°C for 2 h. The samples were then dialyzed for 22 h against 0.15 M NaCl at 4°C with several bath changes.
Preparation of an apolipoprotein B-free Lp(a)-antigen/ lipid complex. The Lp(a) antigen was purified as described earlier (8) . 5 Cell culture. The normal human fibroblast strains used in these experiments were established from skin samples of a 6-yr-old boy and a 10-yr-old girl, removed at the time of surgery because of herniotomia. Receptor negative fibroblasts were cultured from a skin sample that was obtained from a patient with homozygous familial hypercholesterolemia. This patient was a 7-yr-old boy (brother of subject 13 in Table II ). The clinical data are presented below.
Stock cultures were maintained for up to 2 wk in 250-ml plastic culture flasks containing 12 ml growth medium consisting of Eagle's minimal essential medium (MEM) supplemented with penicillin (100 U/ml), streptomycin (1 ,g/ml), 1% nonessential amino acids and 10% (vol/vol) fetal calf serum. The nutrient medium was renewed every 3-4 d and the cells were maintained at 37°C in a humidified 95% air-5% CO2 atmosphere.
Experiments were carried out between the 10th and 25th passage. Cells from stock flasks were dissociated with trypsin-EDTA (0.05%) at 37°C and seeded (day 0) at a concentration of "-1 X 105 cells/2 ml of media in each well of FB6-TC multi-dish trays. On day 3, the medium was replaced with 2 ml of fresh standard growth medium. At day 5, the monolayers were washed with phosphate-buffered saline, after which Specific binding of '2I-Lp(a) or 1251-LDL was defined as total binding minus (nonspecific) binding seen in the presence of either unlabeled Lp(a) or LDL, at 500-Ag/ml concentrations. Binding activity is expressed as moles of radioligand bound to cells per culture dish, assuming a molecular weight of 5.6 X 106 for Lp(a) (11) and 3 X 106 for LDL (33 Calculations. It is well established that the apoproteins of LDL (35) and Lp(a) (14) are not removed from the lipoprotein particle within the plasma. Since >96% of the radioactivity of the labeled Lp(a) and LDL was bound to the apolipoprotein, the turnover parameters of Lp(a) and LDL could be calculated directly from the die-away curves of 1251 and 1311 in the serum. In each subject, the serum decay curves of Lp(a) and LDL could be resolved into two exponential components indicating a two-compartment model as already demonstrated for these two lipoproteins (14, 15) . (Table II) after intravenous injection of 125I-Lp(a) (@) and "'3I-LDL (0). (Fig. 2) . The maximum binding capacities for Lp(a) and LDL were calculated from the Scatchard plots (43) of six independent experiments using fibroblasts of two different cell lines. Fig. 2 Table I .
Competition binding studies. The specificity of the binding of '251-Lp(a) to intact human fibroblasts was probed by competition studies utilizing unlabeled Lp(a) and LDL. The relative affinity of the unlabeled ligands is reflected by their relative potency in competing with 1251-Lp(a) for these binding sites (Fig. 3) . Specificity of 125I-LDL binding sites was assessed for control purposes (Fig. 3) .
When HDL were used to compete with '251-Lp(a) for the binding sites, -100 times as much HDL (by weight) was required for 50% inhibition of '251-Lp(a) binding.
In another set of experiments a binding study with a Lp(a)-antigen-lipid complex was performed. Absolutely no specific binding of this particle to human fibroblasts could be observed.
Effect of cyclohexanedione. difference between percent intravascular of Lp(a) and LDL was highly significant (median of the differences: 10.75, P < 0.01). A highly significant positive correlation was found between FCR of LDL and FCR of Lp(a) (Spearman rank correlation: r = 0.853, P < 0.01) (Fig. 5) . No relationship could be demonstrated between the serum concentration of Lp(a) and LDL-apolipoprotein B (r = 0.311). In agreement with previous results (14) , a highly significant positive relationship between the absolute synthetic rate and the serum concentration of Lp(a) (r = 0.979, P < 0.01) was obtained. A negative, but statistically insignificant correlation was found between the FCR and the serum level of Lp(a) (r (Fig. 6) . No correlation between the synthetic rate of LDL-apolipoprotein B and the serum level of LDL-apolipoprotein B was found (r = 0.089).
Turnover study in the patient with homozygous FH. The kinetic parameters of the patient with homozygous FH are presented in Table II 6 Relationship between FCR of LDL and the concentration of LDL-apolipoprotein B in the serum of normolipemic subjects (r = -0.613, P < 0.05).
dividuals. In contrast to LDL, the synthetic rate of Lp(a) was low. This explains the relatively low Lp(a) serum concentration in this FH patient.
DISCUSSION
The specific receptor-mediated catabolic pathway of LDL has been shown to play a major role in the regulation of the LDL metabolism (19, 20, 23) . Goldstein and Brown (23) calculated from their own experiments and from kinetic data of others that in normolipemic subjects -30% of the plasma pool is daily cleared by the receptor pathway, and -15% of the plasma LDL is daily removed and catabolized via a nonreceptor route ("scavenger pathway").
In view of the similarities between Lp(a) and LDL with regard to their physicochemical properties, characteristics of Lp(a) binding sites were assessed by means of direct binding studies with '251-Lp(a). Sat (25) showed that modification of the arginyl residues of apolipoprotein B by cyclohexanedione abolished binding of LDL to high affinity cell surface receptors of human fibroblasts. In our experiments, cyclohexanedione treatment of Lp(a) and LDL resulted in a complete loss of specific binding of both lipoproteins. From this result it is suggested that similar recognition sites on both lipoproteins are responsible for specific binding to the receptor. The binding experiments with apolipoprotein B-free Lp(a)-antigen/lipid particles indicate that the specific Lp(a) antigen is not bound by the receptor. Therefore, similarly to LDL, the apolipoprotein B moiety of Lp(a) seems to be responsible for the recognition by the receptor.
Under the assumption that Lp(a) and LDL bind to the same type of receptor, the differences in affinity and binding capacity could be due to the larger molecular weight of the Lp(a) particles, which is approximately twice as high as LDL (11, 33) . On the other hand, the specific Lp(a) antigen could possibly mask some of the apolipoprotein B recognition sites leading to altered steric effects of binding.
The inhibition of HMG-CoA reductase activity after binding of Lp(a) to the fibroblasts indicates that Lp(a) is taken up into the cells and regulates intracellular cholesterol metabolism in a similar way as LDL. Lp(a) seems to be less effective than LDL in suppressing HMG-CoA reductase activity. This could be a consequence of the lower affinity to the receptor.
There is, however, one major drawback to the hypothesis of a simple monocomponent binding system for LDL and Lp(a). If only one type of receptor exists with high affinity to LDL and a somewhat lower affinity to Lp(a), one would expect that unlabeled LDL is more potent than Lp(a) in competing for 1251-Lp(a) binding sites. No significant difference between these two lipoproteins in competing for the binding sites, however, was found. Therefore the results of this study do not definitely rule out the possibility of a multicomponent receptor system. One could, for instance, speculate that the receptor-protein exists in two different conformations for Lp(a) and LDL. The theoretical possibility that the LDL receptor is a multicomponent molecule that possesses at least two discrete active sites, has been mentioned by Brown and Goldstein (44) in another context.
In a previous study turnover parameters of Lp(a) (14) were found to be similar to those of LDL as reported by others (15) (16) (17) (18) . In the present study the turnover of Lp(a) Although a close correlation between the FCR of Lp(a) and LDL was obtained, no relationship was found between the serum levels of these two lipoproteins. The lack of correlation between Lp(a) and LDL serum levels has also been observed by others (12) . For Lp(a), no relationship between the FCR and the serum level, but a highly significant correlation between the synthetic rate and the serum concentration was found. This is in agreement with our previous finding that the Lp(a) serum concentration is mainly regulated by the synthetic rate of this lipoprotein (14) . The synthetic rate of Lp(a) (Table II) 
